The prognosis for patients with EPS largely depends on the type and severity of symptoms, as well as the timeliness of intervention. In many cases, reducing the offending agent or implementing treatment strategies can significantly improve symptoms. However, tardive dyskinesia may persist even after discontinuation of the causative drug, making early detection and management crucial.
In conclusion, extrapyramidal symptoms represent a complex interplay between medication use and neurological function. Through vigilant monitoring, prompt diagnosis, and effective management, the burden of these symptoms can be minimized, improving the quality of life for affected individuals.
